tiprankstipranks
Trending News
More News >
Krystal Biotech, Inc. (KRYS)
:KRYS
US Market
Advertisement

Krystal Biotech (KRYS) Stock Forecast & Price Target

Compare
544 Followers
See the Price Targets and Ratings of:

KRYS Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Krystal
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KRYS Stock 12 Month Forecast

Average Price Target

$197.56
▲(43.84% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $197.56 with a high forecast of $240.00 and a low forecast of $166.00. The average price target represents a 43.84% change from the last price of $137.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","241":"$241","153.25":"$153.3","182.5":"$182.5","211.75":"$211.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":197.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$197.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$166.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,153.25,182.5,211.75,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.98,163.36615384615385,169.75230769230768,176.13846153846154,182.52461538461537,188.91076923076923,195.29692307692306,201.68307692307692,208.06923076923076,214.45538461538462,220.84153846153845,227.2276923076923,233.61384615384617,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.98,160.10153846153844,163.22307692307692,166.34461538461537,169.46615384615384,172.5876923076923,175.70923076923077,178.83076923076922,181.9523076923077,185.07384615384615,188.19538461538463,191.31692307692308,194.43846153846152,{"y":197.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.98,157.67384615384614,158.3676923076923,159.06153846153845,159.7553846153846,160.44923076923075,161.1430769230769,161.83692307692309,162.53076923076924,163.2246153846154,163.91846153846154,164.6123076923077,165.30615384615385,{"y":166,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":198.78,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$240.00Average Price Target$197.56Lowest Price Target$166.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on KRYS
TipRanks AITipRanks
Not Ranked
TipRanks
$149
Buy
8.48%
Upside
Reiterated
08/05/25
Krystal Biotech's overall stock score is primarily driven by its strong financial performance and positive corporate developments, such as regulatory approvals and clinical advancements. Technical and valuation metrics present some concerns, but the company's strategic initiatives and growth prospects contribute positively to its outlook.
TD Cowen Analyst forecast on KRYS
Ritu BaralTD Cowen
TD Cowen
$202
Buy
47.07%
Upside
Reiterated
08/04/25
Krystal Biotech's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
Citi
$176$166
Hold
20.86%
Upside
Reiterated
08/04/25
Citi Sticks to Their Hold Rating for Krystal Biotech (KRYS)
William Blair Analyst forecast on KRYS
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
08/04/25
Krystal Biotech: Strong Financial Performance and Strategic Growth Initiatives Support Buy Rating
Bank of America Securities Analyst forecast on KRYS
Alec StranahanBank of America Securities
Bank of America Securities
$192$182
Buy
32.51%
Upside
Reiterated
08/04/25
Krystal Biotech price target lowered to $182 from $192 at BofAKrystal Biotech price target lowered to $182 from $192 at BofA
H.C. Wainwright Analyst forecast on KRYS
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$240
Buy
74.74%
Upside
Reiterated
08/04/25
Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating
Cantor Fitzgerald Analyst forecast on KRYS
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$215
Buy
56.53%
Upside
Reiterated
07/30/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Krystal Biotech (KRYS)
Goldman Sachs Analyst forecast on KRYS
Andrea NewkirkGoldman Sachs
Goldman Sachs
$194
Buy
41.24%
Upside
Reiterated
07/25/25
Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential
Evercore ISI
$200
Buy
45.61%
Upside
Reiterated
07/24/25
Krystal Biotech (KRYS) Receives a Buy from Evercore ISI
Clear Street Analyst forecast on KRYS
William MaughanClear Street
Clear Street
$190
Buy
38.33%
Upside
Initiated
06/30/25
Krystal Biotech initiated with a Buy at Clear StreetKrystal Biotech initiated with a Buy at Clear Street
Guggenheim
$195$189
Buy
37.60%
Upside
Reiterated
05/07/25
Krystal Biotech price target lowered to $189 from $195 at GuggenheimKrystal Biotech price target lowered to $189 from $195 at Guggenheim
Jefferies Analyst forecast on KRYS
Roger SongJefferies
Jefferies
$245
Buy
78.38%
Upside
Initiated
03/05/25
Krystal Biotech's Growth Potential: Strong Vyjuvek Launch and Promising PipelineWe see steady growth to achieve blockbuster status in few years, deepening penetration by accessing global and ocular market. Co has many dev program in CF/ AATD/ oncology/ dermatology based on proprietary, in house gene delivery technology to drive add'l upside. We initiate at Buy with PT of $245.
Chardan Capital Analyst forecast on KRYS
Geulah LivshitsChardan Capital
Chardan Capital
$212$218
Buy
58.72%
Upside
Reiterated
02/19/25
Krystal Biotech price target raised to $218 from $212 at ChardanKrystal Biotech price target raised to $218 from $212 at Chardan
Stifel Nicolaus Analyst forecast on KRYS
Dae Gon HaStifel Nicolaus
Stifel Nicolaus
$220
Buy
60.17%
Upside
Reiterated
11/05/24
Stifel Nicolaus Sticks to Their Buy Rating for Krystal Biotech (KRYS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on KRYS
TipRanks AITipRanks
Not Ranked
TipRanks
$149
Buy
8.48%
Upside
Reiterated
08/05/25
Krystal Biotech's overall stock score is primarily driven by its strong financial performance and positive corporate developments, such as regulatory approvals and clinical advancements. Technical and valuation metrics present some concerns, but the company's strategic initiatives and growth prospects contribute positively to its outlook.
TD Cowen Analyst forecast on KRYS
Ritu BaralTD Cowen
TD Cowen
$202
Buy
47.07%
Upside
Reiterated
08/04/25
Krystal Biotech's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
Citi
$176$166
Hold
20.86%
Upside
Reiterated
08/04/25
Citi Sticks to Their Hold Rating for Krystal Biotech (KRYS)
William Blair Analyst forecast on KRYS
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
08/04/25
Krystal Biotech: Strong Financial Performance and Strategic Growth Initiatives Support Buy Rating
Bank of America Securities Analyst forecast on KRYS
Alec StranahanBank of America Securities
Bank of America Securities
$192$182
Buy
32.51%
Upside
Reiterated
08/04/25
Krystal Biotech price target lowered to $182 from $192 at BofAKrystal Biotech price target lowered to $182 from $192 at BofA
H.C. Wainwright Analyst forecast on KRYS
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$240
Buy
74.74%
Upside
Reiterated
08/04/25
Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating
Cantor Fitzgerald Analyst forecast on KRYS
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$215
Buy
56.53%
Upside
Reiterated
07/30/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Krystal Biotech (KRYS)
Goldman Sachs Analyst forecast on KRYS
Andrea NewkirkGoldman Sachs
Goldman Sachs
$194
Buy
41.24%
Upside
Reiterated
07/25/25
Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential
Evercore ISI
$200
Buy
45.61%
Upside
Reiterated
07/24/25
Krystal Biotech (KRYS) Receives a Buy from Evercore ISI
Clear Street Analyst forecast on KRYS
William MaughanClear Street
Clear Street
$190
Buy
38.33%
Upside
Initiated
06/30/25
Krystal Biotech initiated with a Buy at Clear StreetKrystal Biotech initiated with a Buy at Clear Street
Guggenheim
$195$189
Buy
37.60%
Upside
Reiterated
05/07/25
Krystal Biotech price target lowered to $189 from $195 at GuggenheimKrystal Biotech price target lowered to $189 from $195 at Guggenheim
Jefferies Analyst forecast on KRYS
Roger SongJefferies
Jefferies
$245
Buy
78.38%
Upside
Initiated
03/05/25
Krystal Biotech's Growth Potential: Strong Vyjuvek Launch and Promising PipelineWe see steady growth to achieve blockbuster status in few years, deepening penetration by accessing global and ocular market. Co has many dev program in CF/ AATD/ oncology/ dermatology based on proprietary, in house gene delivery technology to drive add'l upside. We initiate at Buy with PT of $245.
Chardan Capital Analyst forecast on KRYS
Geulah LivshitsChardan Capital
Chardan Capital
$212$218
Buy
58.72%
Upside
Reiterated
02/19/25
Krystal Biotech price target raised to $218 from $212 at ChardanKrystal Biotech price target raised to $218 from $212 at Chardan
Stifel Nicolaus Analyst forecast on KRYS
Dae Gon HaStifel Nicolaus
Stifel Nicolaus
$220
Buy
60.17%
Upside
Reiterated
11/05/24
Stifel Nicolaus Sticks to Their Buy Rating for Krystal Biotech (KRYS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

1 Month
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+7.75%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +7.75% per trade.
3 Months
xxx
Success Rate
7/12 ratings generated profit
58%
Average Return
+6.68%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +6.68% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
13/16 ratings generated profit
81%
Average Return
+40.05%
reiterated a buy rating 6 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +40.05% per trade.
2 Years
xxx
Success Rate
13/16 ratings generated profit
81%
Average Return
+82.12%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +82.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRYS Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
2
5
7
6
Buy
21
20
21
27
22
Hold
1
2
2
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
24
28
37
30
In the current month, KRYS has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KRYS average Analyst price target in the past 3 months is 197.56.
Each month's total comprises the sum of three months' worth of ratings.

KRYS Financial Forecast

KRYS Earnings Forecast

Next quarter’s earnings estimate for KRYS is $1.16 with a range of $0.85 to $1.54. The previous quarter’s EPS was $1.29. KRYS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year KRYS has Preformed in-line its overall industry.
Next quarter’s earnings estimate for KRYS is $1.16 with a range of $0.85 to $1.54. The previous quarter’s EPS was $1.29. KRYS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year KRYS has Preformed in-line its overall industry.

KRYS Sales Forecast

Next quarter’s sales forecast for KRYS is $93.34M with a range of $91.20M to $96.50M. The previous quarter’s sales results were $96.04M. KRYS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year KRYS has Preformed in-line its overall industry.
Next quarter’s sales forecast for KRYS is $93.34M with a range of $91.20M to $96.50M. The previous quarter’s sales results were $96.04M. KRYS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year KRYS has Preformed in-line its overall industry.

KRYS Stock Forecast FAQ

What is KRYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Krystal Biotech, Inc.’s 12-month average price target is 197.56.
    What is KRYS’s upside potential, based on the analysts’ average price target?
    Krystal Biotech, Inc. has 43.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KRYS a Buy, Sell or Hold?
          Krystal Biotech, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Krystal Biotech, Inc.’s price target?
            The average price target for Krystal Biotech, Inc. is 197.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $240.00 ,the lowest forecast is $166.00. The average price target represents 43.84% Increase from the current price of $137.35.
              What do analysts say about Krystal Biotech, Inc.?
              Krystal Biotech, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of KRYS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis